

Financial Highlights

(Billions of yen)

		FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Estimate FY2015 (Jan-Dec) (Forecast as of Nov 2015)
Net sales	(Billions of yen)	1,154.6	1,218.1	1,452.8	1,224.3	1,135.8	1,107.2	1,410.0
	YoY	2.4%	5.5%	19.3%	7.9%		-2.5%	
Operating income	(Billions of yen)	148.7	169.7	198.7	196.5	154.0	147.1	145.0
	YoY	17.7%	14.1%	17.1%	7.4%		-4.5%	
Ordinary income	(Billions of yen)	152.1	184.5	215.2	217.2	166.6	155.3	150.0
	YoY	18.5%	21.3%	16.7%	8.9%		-6.8%	
Net income	(Billions of yen)	92.2	122.4	151.0	143.1	111.5	103.1	90.0
	YoY	11.9%	32.8%	23.3%	2.7%		-7.5%	
R&D expenses	(Billions of yen)	159.2	192.4	249.0	172.9	179.7	141.9	200.0
	YoY	-3.3%	20.8%	29.4%	4.6%		-21.1%	
Overseas net sales	(Billions of yen)	579.7	622.7	824.4	757.0	686.5	635.9	771.0
	% of net sales	50.2%	51.1%	56.8%	61.8%	60.4%	57.4%	

(Yen)

Exchange rate (Yen)	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Estimate FY2015 (Jan-Dec) (Forecast as of Nov 2015)
US\$	79.79	79.80	97.72	106.72	102.93	120.98	121.00
Euro	111.12	102.55	129.77	140.20	139.50	134.74	135.00

(Billions of yen)

Selling, general and administrative expenses	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Estimate FY2015 (Jan-Dec) (Forecast as of Nov 2015)
Selling, general and administrative expenses	616.6	654.6	812.4	681.5	655.7	625.7	820.0
(% of net sales)	53.4%	53.7%	55.9%	55.7%	57.7%	56.5%	58.2%
Promotion expenses	174.4	156.2	192.0	188.0	171.1	160.5	
Personnel expenses	99.8	103.7	124.0	97.9	99.3	112.0	
Advertising expenses	25.1	29.5	34.2	26.0	23.5	25.1	
R&D expenses	159.2	192.4	249.0	172.9	179.7	141.9	200.0
(% of net sales)	13.8%	15.8%	17.1%	14.1%	15.8%	12.8%	14.2%
R&D expenses of pharmaceutical business	149.3	183.5	240.8	166.1	172.7	134.9	190.0

(Billions of yen)

Capital expenditures	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Estimate FY2015 (Jan-Dec) (Forecast as of Nov 2015)
Capital expenditures	43.3	63.3	179.0	88.2	59.6	502.0	520.0

(Billions of yen)

Depreciation	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Estimate FY2015 (Jan-Dec) (Forecast as of Nov 2015)
Depreciation	48.1	45.5	49.8	45.5	43.3	53.2	72.0

Consolidated Statements of Income

(Billions of yen)

	FY2011	%	FY2012	%	FY2013	%	FY2014 (Apr-Dec)	%	FY2014 (Jan-Sep)	%	3Q FY2015 (Jan-Sep)	%	Change
Net sales	1,154.6	100.0%	1,218.1	100.0%	1,452.8	100.0%	1,224.3	100.0%	1,135.8	100.0%	1,107.2	100.0%	-2.5%
Cost of sales	389.3	33.7%	393.8	32.3%	441.6	30.4%	346.3	28.3%	326.2	28.7%	334.4	30.2%	2.5%
Gross profit	765.3	66.3%	824.2	67.7%	1,011.1	69.6%	878.0	71.7%	809.7	71.3%	772.7	69.8%	-4.6%
Selling, general and administrative expenses	616.6	53.4%	654.6	53.7%	812.4	55.9%	681.5	55.7%	655.7	57.7%	625.7	56.5%	-4.6%
Promotion expenses	174.4		156.2		192.0		188.0		171.1		160.5		
Salaries and bonuses	81.3		85.4		107.1		89.9		84.3		95.9		
Reserve for bonuses	9.8		9.5		11.2		5.3		11.1		13.3		
Retirement benefit expenses	7.7		7.8		4.6		1.7		2.7		2.4		
Provision for directors' and audit & supervisory board members' retirement benefits	0.7		0.6		0.5		0.3		0.3		-		
Provision for directors' bonuses	0.4		0.3		0.6		0.6		0.9		-		
Depreciation	14.7		14.5		16.9		22.9		19.7		-		
Amortization of goodwill	4.7		4.8		3.7		3.8		3.4		10.5		
Research and development expenses	159.2	13.8%	192.4	15.8%	249.0	17.1%	172.9	14.1%	179.7	15.8%	141.9	12.8%	-21.1%
Other	163.8		183.0		226.7		196.0		182.5		201.2		
Operating income	148.7	12.9%	169.7	13.9%	198.7	13.7%	196.5	16.1%	154.0	13.6%	147.1	13.3%	-4.5%
Non-operating income	8.6		16.6		18.8		23.1		14.6		14.4		
Interest income	1.6		1.4		1.3		1.3		1.0		1.2		
Dividend income	1.3		1.5		1.3		1.0		0.9		1.1		
Amortization of negative goodwill	2.5		2.5		2.6		1.8		1.8		2.1		
Equity in earnings of unconsolidated subsidiaries and affiliates	1.2		3.1		3.2		3.9		7.1		8.1		
Foreign exchange gain, net	-		6.2		7.9		12.9		1.8		-		
Other	2.1		2.0		2.5		2.3		1.9		1.9		
Non-operating expenses	5.2		1.8		2.3		2.4		1.9		6.2		
Interest expenses	1.7		1.2		1.2		1.7		1.3		2.9		
Foreign exchange loss, net	2.7		-		-		-		-		2.5		
Other	0.7		0.6		1.1		0.8		0.6		0.8		
Ordinary income	152.1	13.2%	184.5	15.1%	215.2	14.8%	217.2	17.7%	166.6	14.7%	155.3	14.0%	-6.8%
Extraordinary income	1.2		0.3		2.0		1.4		0.8		1.5		
Gain on sales of fixed assets	0.2		0.1		0.5		0.1		0.1		0.7		
Gain on change in equity	0.3		-		-		-		0.1		-		
Gain on sales of investment securities	-		-		0.3		0.0		0.3		-		
Gain on sales of shares of subsidiaries	-		-		0.3		-		-		-		
Subsidy income	-		-		0.9		0.9		-		0.4		
Gain on insurance adjustment	-		-		-		-		-		0.3		
Other	0.6		0.1		0.0		0.4		0.3		0.1		
Extraordinary loss	10.9		7.8		7.0		8.4		5.9		1.6		
Loss on retirement of fixed assets	0.6		0.7		0.9		0.6		0.7		0.2		
Impairment loss	2.7		2.6		3.4		5.4		2.0		0.2		
Loss on valuation of investment securities	3.7		4.4		0.2		1.5		0.2		0.4		
Extra retirement payments	-		-		1.9		0.6		2.5		-		
Provision of allowance for investment loss	-		-		-		-		-		-		
Loss on transfer of business	0.7		-		-		-		-		-		
Provision for loss on business liquidation	2.2		-		-		-		-		-		
Disaster related loss	0.3		-		-		-		-		-		
Loss on sales of shares of subsidiaries and associates	-		-		-		-		-		0.6		
Other	0.8		0.1		0.6		0.4		0.5		0.2		
Income before income taxes and minority interests	142.4		176.9		210.2		210.3		161.5		155.1		
Income taxes-current	55.0		62.0		81.3		46.2		60.2		27.0		
Income taxes-deferred	-5.4		-8.2		-23.6		19.8		-11.3		24.1		
Total income taxes	49.6		53.8		57.7		66.1		48.9		51.1		4.5%
Minority interests in net income	0.6		0.7		1.6		1.1		1.0		0.9		
Net income	92.2	8.0%	122.4	10.1%	151.0	10.4%	143.1	11.7%	111.5	9.8%	103.1	9.3%	-7.5%

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Change
Consolidated sales	1,154.6	1,218.1	1,452.8	1,224.3	1,135.8	1,107.2	-2.5%
Pharmaceutical business	782.2	850.9	1,035.1	883.5	819.7	753.9	-8.0%
Japan	326.5	351.8	372.9	273.7	260.7	277.6	6.5%
North America	361.1	389.0	530.5	481.6	440.8	296.5	-32.7%
Others	94.7	110.0	131.7	128.3	118.2	179.7	52.1%
Nutraceutical business	251.3	246.9	281.1	232.7	210.9	240.4	14.0%
Japan	147.4	142.3	147.5	109.8	106.4	110.1	3.4%
North America	45.8	49.8	59.8	55.8	40.9	57.8	41.2%
Others	58.1	54.8	73.9	67.1	63.6	72.5	14.1%
Consumer products business	48.0	45.2	43.8	34.4	33.6	33.2	-1.2%
Japan	42.0	39.2	36.6	27.9	27.2	25.3	-7.1%
North America	5.4	5.4	6.9	6.1	6.1	7.5	23.5%
Others	0.6	0.6	0.3	0.3	0.3	0.4	42.2%
Other business	73.1	75.0	92.8	73.7	71.6	79.7	11.4%
Japan	59.1	62.0	71.4	55.9	54.9	58.3	6.2%
North America	1.3	1.4	2.3	1.8	1.7	1.4	-19.1%
Others	12.7	11.6	19.0	16.0	14.9	20.0	34.2%
Japan -total	574.9	595.3	628.3	467.3	449.3	471.2	4.9%
North America - total	413.5	445.7	599.6	545.3	489.6	363.2	-25.8%
Others - total	166.2	177.1	224.9	211.7	196.9	272.7	38.5%
Overseas net sales	579.7	622.7	824.4	757.0	686.5	635.9	-7.4%
Overseas net sales ratio	50.2%	51.1%	56.8%	61.8%	60.4%	57.4%	

Net Sales and Operating Income by Geographical and Business Segment

(1) Geographical segment

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Change
Net sales	1,154.6	1,218.1	1,452.8	1,224.3	1,135.8	1,107.2	-2.5%
Japan*	779.1	842.5	982.1	738.2	723.2	629.4	-13.0%
North America*	437.5	474.1	652.1	601.9	531.1	419.7	-21.0%
Others*	142.4	138.2	204.4	189.6	179.5	196.8	9.6%
Eliminations/corporate	-204.4	-236.7	-385.9	-305.4	-298.1	-138.7	

*Intersegment sales are included.

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Change
Operating income	148.7	169.7	198.7	196.5	154.0	147.1	-4.5%
Japan	142.5	160.8	217.5	156.2	149.8	88.5	-40.9%
North America	14.4	16.2	-5.0	12.8	4.2	2.1	-50.9%
Others	3.7	6.4	1.9	16.8	8.6	26.2	205.0%
Eliminations/corporate	-12.0	-13.8	-15.7	10.7	-8.7	30.3	

(2) Business segment

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Change
Net sales	1,154.6	1,218.1	1,452.8	1,224.3	1,135.8	1,107.2	-2.5%
Pharmaceutical business*	782.2	850.9	1,035.1	883.5	819.7	753.9	-8.0%
Nutraceutical business*	254.8	251.8	287.1	238.2	215.9	246.7	14.3%
Consumer products business*	49.2	46.9	43.9	34.5	33.7	33.4	-0.8%
Other business*	108.6	111.7	130.3	102.2	99.7	107.5	7.8%
Eliminations/corporate	-40.3	-43.1	-43.7	-34.2	-33.3	-34.4	

*Intersegment sales are included.

(Billions of yen)

	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year <unaudited>	3Q FY2015 (Jan-Sep)	Change
Operating income	148.7	169.7	198.7	196.5	154.0	147.1	-4.5%
Pharmaceutical business	168.5	187.9	212.8	204.8	165.3	148.4	-10.2%
Nutraceutical business	22.1	21.4	25.4	21.9	15.6	24.7	58.7%
Consumer products business	-2.3	-2.4	-2.2	-1.4	-0.4	-2.6	
Other business	1.9	3.9	7.2	5.5	5.6	5.1	-9.3%
Eliminations/corporate	-41.6	-41.0	-44.5	-34.3	-32.0	-28.4	

【Pharmaceutical business】

(Billions of yen)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year (unaudited)	3Q FY2015 (Jan-Sep)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Nov 2015)
Antipsychotic agent Abilify	Otsuka Pharmaceutical	411.6	438.5	575.7	507.4	472.5	291.1	-38.4%	325.0
North America		316.1	336.1	455.5	416.5	369.9	210.5	-43.1%	224.0
<US\$ million>		<3,960>	<4,208>	<4,659>	<3,900>	<3,592>	<1,740>	-51.6%	<1,850>
Japan		24.8	28.6	34.4	23.7	23.7	25.9	9.2%	37.0
Others		70.7	73.9	85.8	67.2	78.8	54.7	-30.6%	64.0
Aripiprazole long acting injection Abilify Maintena	Otsuka Pharmaceutical			4.3	14.4	11.0	28.2	157.7%	41.0
Anti-platelet agent Pletaal/Pletal	Otsuka Pharmaceutical	50.3	45.8	44.2	26.2	26.6	23.4	-12.1%	31.5
Japan		44.1	40.1	36.8	20.7	21.1	17.3	-18.2%	23.5
Others		6.2	5.7	7.4	5.5	5.5	6.1	11.2%	8.0
Anti-gastritis and anti-gastric ulcer agent Mucosta	Otsuka Pharmaceutical	28.7	23.0	22.0	12.9	13.3	11.9	-10.5%	16.0
Japan		26.0	20.5	18.8	10.1	10.7	8.5	-20.7%	11.5
Others		2.7	2.5	3.1	2.7	2.6	3.4	30.5%	4.5
Anti-metabolite TS-1	Taiho Pharmaceutical	36.5	37.0	37.4	24.0	22.4	21.9	-1.9%	29.0
Anti-metabolite UFT	Taiho Pharmaceutical	12.9	11.2	9.5	6.3	6.1	5.5	-9.8%	7.0
Reduced folic acid formulation Uzel	Taiho Pharmaceutical	12.7	13.2	11.9	7.9	7.7	7.7	0.2%	10.0
Anticancer Lonsurf	Taiho Pharmaceutical				2.3	1.5	2.4	60.4%	5.0
Urinary incontinence / frequency treatment Bup-4	Taiho Pharmaceutical	6.3	5.6	4.7	2.8	2.8	2.4	-14.8%	3.5
5-HT ₃ receptor antagonist Aloxi	Taiho Pharmaceutical	7.9	10.0	11.0	8.8	8.1	9.3	14.9%	12.5
Anticancer Abraxane	Taiho Pharmaceutical	3.2	3.7	8.8	8.2	7.4	14.6	96.0%	20.0
Antiepileptic E Keppra	Otsuka Pharmaceutical	4.8	10.5	15.8	13.2	12.3	16.4	33.8%	23.5
V ₂ receptor antagonist Samsca/ Jinarc	Otsuka Pharmaceutical	6.7	12.8	21.0	20.8	19.0	29.4	54.9%	40.0
Mucin-production enhancing agent Mucosta Ophthalmic Suspension	Otsuka Pharmaceutical	0.1	1.0	2.9	2.8	2.6	3.2	24.9%	5.0
Parkinson's Disease, RLS ⁺ treatment Neupro Patch	Otsuka Pharmaceutical		0.2	2.6	4.7	3.7	5.8	55.7%	8.5
Anticancer Sprycel (collaboration with BMS)	Otsuka Pharmaceutical	7.6	12.0	26.1	22.9	20.4	23.9	16.9%	31.5
Antibiotic Zosyn/Tazocin (bulk supply)	Taiho Pharmaceutical	10.7	12.4	14.5	11.8	12.4	9.0	-27.4%	13.5
Diagnostics -total	Otsuka Pharmaceutical	7.9	8.8	12.6	8.5	9.2	8.6	-7.3%	12.5
Parenteral nutrition (clinical nutrition) -total		96.0	96.4	103.4	81.5	75.2	76.5	1.7%	106.0
Japan	Otsuka Pharmaceutical Factory	88.6	88.8	91.6	68.2	63.2	64.1	1.4%	87.5
Others		7.4	7.6	11.8	13.3	12.0	12.5	3.5%	18.5
Pharmaceutical business -total (excluding exports)	Japan	326.5	351.8	372.9	273.7	260.7	277.6	6.5%	381.0
Pharmaceutical business -total	Total	782.2	850.9	1,035.1	883.5	819.7	753.9	-8.0%	936.0
Milestone and upfront revenue		14.9	41.5	22.0	20.4	18.8	64.5	242.7%	66.0

【Neutraceuticals business】

(10 thousand cases)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year -unaudited-	3Q FY2015 (Jan-Sep)	Change
Pocari Sweat 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical							
Japan		2,912	2,709	2,860	2,006	2,030	2,182	7.5%
Overseas		1,963	2,151	2,684	2,256	2,161	2,028	-6.2%
SOYJOY 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical							
Japan		100	88	109	107	94	93	-0.5%
Overseas		20	12	16	12	13	15	9.8%
Oronamin C 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,081	1,067	1,105	830	801	788	-1.7%
Calorie Mate 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	351	335	340	280	260	281	7.8%
Tiovita Drink 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	532	489	402	290	281	256	-9.0%
Solmack (10 thousand of bottles)	Taiho Pharmaceutical	1,579	1,588	1,479	1,174	920	963	4.7%

* Overseas sales include sales of consolidated subsidiaries only.

【Consumer products business】

(10 thousand cases)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year -unaudited-	3Q FY2015 (Jan-Sep)	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	679	567	580	396	395	387	-2.0%
Match 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	451	521	514	447	445	428	-3.9%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	317	300	265	177	165	162	-1.8%

【Other business】

(Billions of yen)

Product name	Company	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Sep) Standardizing the Company's business year -unaudited-	3Q FY2015 (Jan-Sep)	Change
Functional chemicals	Otsuka Chemical	27.9	26.6	33.5	26.6	25.8	25.7	-0.6%
Fine chemicals	Otsuka Chemical	9.3	10.2	10.1	7.3	7.5	7.7	2.7%

Otsuka Group - Pipeline Information

(as of Sep 30, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
<Central nervous system, neurological disorders>						
OPC-14597 <ABILIFY*>	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Autism / Oral	JP	Phase III
<Abilify Maintena*>: Depot injection				Agitation associated with dementia of the Alzheimer's type / Oral	JP	Phase III
				Bipolar I / Depot injection	JP, US, EU	Phase III
L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral, Injection	JP	Filed
OPC-34712 <REXULTI*>	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Major depressive disorder / Oral	US EU	Approved Phase III
				Schizophrenia / Oral	US JP, EU	Approved Phase III
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder (PTSD) / Oral	US, EU	Phase III
Lu AE58054	idalopirdine	Lundbeck	selective 5-HT ₆ receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III
ASC-01	aripiprazole, sertraline	Otsuka Pharmaceutical	Dopamine partial agonist/ Selective serotonin reuptake inhibitor	Major depressive disorder / Oral	JP, Asia	Phase III
AVP-923	dextromethorphan, quinidine	Avanir	NMDA receptor antagonist/ Serotonin and Norepinephrine reuptake inhibitor/ Sigma-1 receptor agonist/ Neuronal nicotinic receptor antagonist	Dyskinesia associated with Parkinson's disease / Oral	US	Phase II
AVP-786	deuterium-modified dextromethorphan, quinidine	Avanir	NMDA receptor antagonist/ Serotonin and Norepinephrine reuptake inhibitor/ Sigma-1 receptor agonist/ Neuronal nicotinic receptor antagonist	Major depressive disorder / Oral	US	Phase II
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Residual schizophrenia symptoms/Oral	US	Phase II
AVP-825	sumatriptan	Avanir	5-HT _{1B/1D} receptor agonist	Acute migraine / Nasal powder	US	Filed
TAS-205		Taiho Pharmaceutical	PGD synthase-inhibitor	Duchenne Muscular Dystrophy (DMD) / Oral	JP	Phase I
Lu AA36143	nalmefene	Lundbeck	Opioid receptor antagonist	Lowering alcohol consumption of alcohol dependence/ Oral	JP	Phase III
Lu AF20513		Lundbeck	β-amyloid vaccine	Preventing progression of Alzheimer's demetia/injection	EU	Phase I

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Sep 30, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
<Oncology>						
S-1 <TS-1> Japan, Korea <Teyuno*> EU	tegafur, gimeracil, oteracil	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Uterocervical cancer / Oral	JP, Asia	Phase III
TAS-102 <Lonsurf>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	US EU Asia	Approved Filed Phase III
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
				Gastric cancer / Oral	JP, Asia	Phase III
<SATIVEX*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
SGL-110	guadecitabine	Astex	Anti-cancer	Ovarian cancer / Injection	US, EU	Phase II
				Hepatocellular carcinoma / Injection	US, EU	Phase II
				Acute Myeloid Leukemia, Myelodysplastic syndrome / Injection	US	Phase II
				Acute Myeloid Leukemia / Injection	US, EU	Phase III
				Acute Myeloid Leukemia / Injection	JP	Phase I
AT13387		Astex	Anti-cancer (Molecular-targeted drug)	Prostate cancer / Injection	US, EU	Phase II
				NSCLC / Injection	US, EU	Phase II
AT7519		Astex	Anti-cancer (Molecular-targeted drug)	Multiple myeloma / Injection	US	Phase II
ASTX727		Astex	Anti-cancer	Myelodysplastic syndrome / Oral	US	Phase I
ASTX660		Astex	Anti-cancer (Molecular-targeted drug)	Solid Tumors , Lymphomas/Oral	US	Phase I
ET-743 <YONDELIS*>	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Approved
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
OPB-111001		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	EU	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-116		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-117		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-119		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	US, EU	Phase I
TAS-120		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-121		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal Cancer / Injection	JP	Phase I
OPC-12759	rebamipide	Otsuka Pharmaceutical	Oral mucosal protectant / mucosal healing agent	Stomatitis associated with cancer chemoradiotherapy / Solution	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
*: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Sep 30, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
<Cardiovascular>						
OPC-41061 <SAMSCA*/JINARC*>	tolvaptan	Otsuka Pharmaceutical	V ₂ receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	US Asia	Phase III Filed
				Cardiac edema / Oral	Asia	Filed
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis/ Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
<Other areas>						
TAC-202	bilastine	Faes Farma	H ₁ receptor antagonist	Allergic rhinitis / Oral	JP	Phase III
				Chronic urticaria, Pruritus associated with skin disease/ Oral	JP	Phase II/III
OPC-67683 <Delyba*>	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	US	Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
OPB-2045G <Olanedine>	olanexidine	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Approved
OPF-105	Amino Acid, Carbohydrate, and Fat Emulsion Injection with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPF-108	Amino Acid and Carbohydrate, and with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Total parenteral nutrition / Injection	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP,US, Asia	Phase II
ACU-4429	emixustat	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II/III
OPA-6566		Otsuka Pharmaceutical	A _{2a} receptor agonist	Glaucoma / Eye Drops	US	Phase I /II
OPC-1085EL	carteolol, latanoprost	Otsuka Pharmaceutical	β receptor antagonist / PGF _{2α} analogue	Glaucoma / Eye Drops	JP	Phase III**
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase II
OPS-2071		Otsuka Pharmaceutical	New quinolone based antibacterial agent	Clostridium difficile infection, enteric infection / Oral	JP,Asia	Phase II
<Diagnostics>						
C13-CAC	Calcium (13C)	Otsuka Pharmaceutical	13C-Calcium Carbonate breath test	For measurement of gastric acidity / In-vivo diagnostic agent	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

* Product names used outside Japan.

** Events after September 30, 2015 OPC-1085L/Glaucoma: filed on October in JP

Otsuka Group - Pipeline Information

Changes in Pipeline information Since June 2015

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	Change from 2Q FY2015
<Central nervous system, neurological disorders>							
OPC-34712 <REXULTI*>	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Major depressive disorder / Oral	US	Approved	Approved (2015/7)
				Schizophrenia / Oral	US	Approved	Approved (2015/7)
AVP-786	deuterium-modified dextromethorphan, quinidine	Avanir	NMDA receptor antagonist/ Serotonin and Norepinephrine reuptake inhibitor/ Sigma-1 receptor agonist/Neuronal nicotinic receptor antagonist	Agitation associated with dementia of the Alzheimer's type / Oral	US	Phase III	Newly Added
				Residual schizophrenia symptoms/Oral	US	Phase II	Newly Added
<Oncology>							
TAS-102 <Lonsurf>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	US	Approved	Approved (2015/9)
ET-743 <YONDELIS*>	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Approved	Approved (2015/9)
ASTX660		Astex	Anti-cancer (Molecular-targeted drug)	Solid Tumors , Lymphomas/Oral	US	Phase I	Newly Added
<Other areas>							
OPB-2045G <Olanedine>	olanexidine	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Approved	Approved (2015/7)
OPS-2071		Otsuka Pharmaceutical	New quinolone based antibacterial agent	Clostridium difficile infection, enteric infection / Oral	JP, Asia	Phase II	Newly Added
<Events after September 30, 2015>							
OPC-1085EL	carteolol, latanoprost	Otsuka Pharmaceutical	β receptor antagonist / PGF2 α analogue	Glaucoma / Eye Drops	JP	Filed	Filed (2015/10)
<Discontinuation of project development>							
Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	
OPC-34712 <REXULTI*>	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	ADHD (Adults) / Oral	US	Phase II	
Reason for discontinuation of project development : The decision to discontinue development was made as a result of R&D strategic reconsideration of OPC:34712.							
<SPRYCEL>	dasatinib	BMS	Anti-cancer (Molecular-targeted drug)	Pancreatic cancer / Oral	US, EU	Phase II	
Reason for discontinuation of project development : Phase II clinical study didn't meet efficacy endpoint.							
OPB-31121		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, Asia	Phase I	
Reason for discontinuation of project development : Phase I clinical study didn't show the satisfied data to move on to the next step.							
OPB-51602		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, US Asia	Phase I	
Reason for discontinuation of project development : Phase I clinical study didn't show the satisfied data to move on to the next step.							
C13-URA	Uracil (2-13C)	Otsuka Pharmaceutical	13C-uracil breath test	For the diagnosis of gastric emptying disorders / In-vivo diagnostic drug	US	Phase II	
Reason for discontinuation of project development : Phase II clinical study didn't exploit performance as diagnostic medicines.							

*: Product names used outside Japan.